Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Xbrane Biopharma AB    XBRANE   SE0007789409

XBRANE BIOPHARMA AB

(XBRANE)
  Report  
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

Xbrane Biopharma : Notice of annual general meeting in Xbrane Biopharma AB

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2019 | 08:00am EDT

The shareholders of Xbrane Biopharma AB, reg. no. 556749-2375, (the 'Company'), are hereby convened to the annual general meeting to be held on Thursday 16 May 2019, at 17.30 p.m. at Baker McKenzie's preemies at Vasagatan 7 in Stockholm.

The doors to the meeting will open at 17.00 p.m.

Right to attend the annual general meeting and notice: Shareholders wishing to attend the annual general meeting must: on the record date, which is Friday 10 May 2019, be registered in the share register maintained by Euroclear Sweden AB. Shareholders, whose shares are registered in the name of a nominee, must temporarily register the shares in their own name at Euroclear Sweden AB. Shareholders whose shares are registered in the name of a nominee must, no later than on Friday 10 May 2019, via their nominee, temporarily register the shares in their own name in order to be entitled to participate at the general meeting and notify their participation at the general meeting no later than Friday 10 May 2019. Notice of participation at the general meeting shall be sent by regular mail to Xbrane Biopharma AB, Banvaktsvagen 22, 171 48 Stockholm or by e-mail to ir@xbrane.com. Upon notification, the shareholder should state their full name, personal identification number or corporate registration number, address and telephone number, and, where applicable, details of representatives, proxy holders and advisors. A shareholder who wishes to be represented by proxy shall issue a written and dated proxy to the proxy holder. If the proxy is issued by a legal entity, a certified copy of the registration certificate or corresponding document ('Registration Certificate') shall be enclosed. The proxy must not be more than one year old, however, the proxy may be older if it is stated that it is valid for a longer term, maximum five years. The proxy in original and the Registration Certificate, if any, must be available at the general meeting and a copy should well before the meeting be sent to the Company by regular mail to Xbrane Biopharma AB, Banvaktsvagen 22, 171 48 Stockholm or by e-mail to ir@xbrane.com , and should, in order to facilitate the entrance to the general meeting, be at the Company's disposal no later than on 10 May 2019. A form proxy will be available for downloading on the Company's website www.xbrane.com.

Contact:

Martin Amark

Tel: +46 (0) 763-093 777

Email: martin.amark@xbrane.com

About Us

Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars. Xbrane has a patented protein production platform for development of biosimilars and world leading expertise in biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name XBRANE and Avanza Bank AB is Xbrane's certified adviser (corp@avanza.se, +46 (0)8 409 421 20).

This information is information that Xbrane Biopharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2019-04-16 14:15 CEST.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on XBRANE BIOPHARMA AB
04/17XBRANE BIOPHARMA : Notice of annual general meeting in Xbrane Biopharma AB
AQ
03/29XBRANE BIOPHARMA : rights issue oversubscribed
AQ
03/14XBRANE BIOPHARMA : and Vator Securities invites to company presentations regardi..
AQ
03/11XBRANE BIOPHARMA : informs that trading in subscription rights and interim share..
AQ
03/08XBRANE BIOPHARMA : and Redeye informs of changed time schedule at the company pr..
AQ
03/07XBRANE BIOPHARMA : publishes published prospectus in connection with fully guara..
AQ
03/01XBRANE BIOPHARMA : The Board of Directors of Xbrane has resolved on a fully guar..
AQ
02/28XBRANE BIOPHARMA : The Board of Directors of Xbrane has resolved on a fully guar..
AQ
02/25XBRANE BIOPHARMA : Releases year-end report for 2018
AQ
02/22XBRANE BIOPHARMA : releases Year-end report for 2018
AQ
More news
Financials (SEK)
Sales 2019 20,0 M
EBIT 2019 -144 M
Net income 2019 -147 M
Finance 2019 51,3 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 13,0x
EV / Sales 2020 17,5x
Capitalization 311 M
Chart XBRANE BIOPHARMA AB
Duration : Period :
Xbrane Biopharma AB Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Martin Åmark Chief Executive Officer
Anders Lennart Tullgren Chairman
Susanna Helgesen Chief Financial Officer & Head-Investor Relations
David Vikström Chief Technology Officer
Dina Jurman Head-Clinical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
XBRANE BIOPHARMA AB33
IQVIA HOLDINGS INC17.40%26 900
LONZA GROUP24.03%23 473
CELLTRION, INC.--.--%19 604
INCYTE CORPORATION28.56%17 530
EXACT SCIENCES CORPORATION48.97%12 511